Biotech Co.* (Country; Symbol)

Pharma Co. (Country)

Type/Product Area

Terms/Details (Date)

Adenosine Therapeutics LLC* on oral drugs for Type II diabetes, asthma and other disorders

Novartis AG (Switzerland)

Option agreement for the A2B receptor antagonist program, which is focused

The Novartis Option Fund invested in Adenosine's Series C financing, which raised $8M in the first closing (6/18)

Ambrx Inc.*

Merck Serono SA (Switzerland)

Exclusive licensing agreement for the pegylated recombinant human growth hormone ARX201

The deal also includes the use of Ambrx's ReCODE pegylation technology to create backup molecules in the HGH space; for worldwide development and commercialization rights, Merck Serono is paying an up-front fee and milestone payments; Ambrx retains the option to co-promote, but, otherwise, is entitled to royalties (6/19)

AnalytiCon Discovery GmbH* (Germany)

Merck KGaA (Germany)

Agreement whereby AnalytiCon will provide Merck with natural product lead-generation services until the end of 2009

AnalytiCon will apply its MEGAbolite technology to seek active compound hits from a set of more than 10,000 extracts from plants and microorganisms; leads would be jointly developed (5/29)

APT Pharmaceuticals Inc.*

Novartis Pharma AG (Switzerland)

Exclusive worldwide rights agreement for an inhalable form of cyclosporine from Novartis

Rights cover use for the prevention and treatment of lung transplant rejection (6/5)

Archemix Inc.*

Merck KGaA (Germany)

Agreement to find drug candidates in cancer and autoimmune and inflammatory disorders

Merck also gets a license to use Selex for internal target validation; the deal is worth $29.8M in up-front equity and includes an option for Merck to buy more stock when Archemix goes public; the agreement is for up to eight products (6/11)

Archemix Inc.*

Takeda Pharmaceutical Co. Ltd. (Japan)

Multi-year, three-target deal

The deal includes a $6M up-front payment plus milestone payments and royalties (6/11)

Avid Radio- pharmaceuticals Inc.*

Bayer Schering Pharma AG (Germany)

Exercised right to license Avid's 18F-AV1/ZK compound

The compound is a molecular imaging agent that targets amyloid plaques in the brain; terms were not disclosed (6/19)

BioSante Pharmaceuticals Inc. (AMEX:BPA)

Teva Pharmaceuticals Industries Ltd. (Israel)

Agreement to restart a collaboration for the development of a male testosterone therapy product for the U.S. market

Teva has agreed to pay BioSante certain milestone payments plus royalties on any sales, and Teva is responsible for continued development of the products (6/12)

BioWa Inc.*

Takeda Pharmaceutical Co. Ltd. (Japan)

Non-exclusive license to BioWa's Potelligent platform for the development of antibody-dependent cellular cytotoxicity enhanced antibodies

BioWa will receive unspecified up-front, license and development milestone fees, as well as royalties (5/30)

Epigentek Group Inc.*

Sigma-Aldrich

Licensing agreement to further develop and com- mercialize technologies for epigenetics research

Sigma-Aldrich gains rights to DNA modification, methylation quantitation and protein/DNA interaction; the agreement is exclusive in the U.S. and co-exclusive globally (6/12)

Gene Logic Inc. (GLGC)

Lundbeck A/S (Denmark)

Drug repositioning and development agreement to seek alternative paths for certain Lundbeck drugs shelved for reasons other than safety

Deal includes discounted milestones and royalties; if Lundbeck opts not to pursue certain candidates, Gene Logic may receive an exclusive license to them and Lundbeck will receive milestone payments and royalties (6/28)

Genexine Co. Ltd.* (South Korea)

Dong-A Pharmaceutical Co. Ltd. (South Korea)

Collaboration covering co- commercialization of first- generation protein drugs under development at Dong-A and co-development of second- generation protein drugs using Genexine's hybrid Fc-fusion technology

They are focused on commercialization for foreign markets of Gonadopin for infertility and of an interferon-beta agent for multiple sclerosis (6/13)

GPC Biotech Inc. (GPCB)

Yakult Honsha Co. Ltd. (Japan)

Agreement for Japanese rights to Satraplatin

Yakult is paying $10M to GPC, and will pay all future development, marketing and sales costs; the deal also includes milestone payments and at least 21% royalties on sales in Japan (6/25)

Immunicon Corp. (IMMC)

Bristol-Myers Squibb Co.

Research services agreement involving protein and molecular targets associated with circulating tumor cells

Further details were not disclosed (6/1)

Indigo Pharmaceuticals Inc.* (Japan)

Nissan Chemical Industries Ltd. and Taisho Pharma- ceutical Co. Ltd.

Agreement for exclusive, worldwide rights to INDI- 702 for cardiovascular indications

Nissan and Taisho retained rights in Japan, South Korea, China and Taiwan; Indigo made an undisclosed up-front payment for the rights (6/1)

InNexus Biotechnology Inc. (Canada; CDNX:IXS; OTC BB:IXSBF)

Royalty Pharma

Agreement in which Royalty purchased a royalty interest in up to two cancer products based on InNexus' Dynamic Cross Linking antibody enhancement technology

Royalty Pharma will buy the first royalty interest for $2M and will hold an option to purchase a royalty interest in a second product for an additional $2M; the total purchase price may be increased by up to $30M if certain conditions are met; Royalty also has purchased 1.1M shares of InNexus for a total additional investment of $1M (6/6)

Life Therapeutics Inc. (PK:LFEFF)

Kedrion SpA (Italy)

Deal for Life to take up a 5.5% equity stake in Kedrion and divest assets from its Life Sera business into a new joint venture company with Kedrion

The deal gives Life Therapeutics exposure to blood fractionation operations (6/25)

Manhattan Pharmaceuticals Inc. (AMEX:MHA)

Thornton & Ross Ltd. (UK)

Agreement for North American rights to develop and commercialize Hedrin, a non-insecticide product candidate for treating head lice

Terms of the deal were not disclosed (6/27)

Medarex Inc. (MEDX)

Mitsubishi Pharma Corp. (Japan)

Collaboration to generate and evaluate fully human monoclonal antibodies against a Mitsubishi target for autoimmune diseases

The companies plan to use Medarex's UltiMAb Human Antibody Development System to generate antibodies for research and possible development; they will share research responsibilities (5/31)

Novacea Inc. (NOVC)

Schering-Plough Corp.

Partnership for the late-stage prostate cancer drug, Asentar

The agreement entails a $60M up front payment and the potential for $380M in milestone payments; Novacea also is entitled to tiered royalties in the range of the high teens to the mid-20s, and it holds a co-commercialization option (5/30)

Noven Pharmaceuticals Inc. (NOVN)

Shire plc (UK)

Exercised option agreement for Shire to acquire exclusive development rights to a new transdermal patch for ADHD to be formulated by Noven

Noven will receive an unspecified amount from Shire for continuing development efforts (6/20)

Renovo Group plc (UK; LSE:RNVO)

Shire plc (UK)

Agreement for the anti- scarring drug Juvista

Shire is paying $125M up front, up to $175M in regulatory milestone payments and up to $525M in commercial milestone payments; Renovo retained the right to commercialize Juvista in EU member states and will cover the costs of trials for EU approval; deal also includes royalties (6/20)

Stem Cell Innovations Inc. (OTC BB:SCLL)

TNO Pharma (the Netherlands)

Collaboration to develop new strategies to control human stem cell differentiation into cartilage and cardiomyocytes

Specific terms were not disclosed (5/30)

SurModics Inc. (SRDX)

Merck & Co. Inc.

Agreement covering development and commercialization of SurModics' Ivation implant- based sustained delivery system

The deal focuses on triamcinolone acetonide for diabetic macular edema and other Merck compounds to treat retinal diseases; SurModics gets an up-front licensing fee of $20M and could get up to $288M more in fees and development milestones through U.S. and EU regulatory approvals; SurModics also will receive royalties (6/27)

Toyama Chemical Co. Ltd. (Japan; FSE:TYA)

Hoffmann-La Roche Inc.

Licensing agreement for the worldwide research, development and commercialization of Toyama's oral rheumatoid arthritis agent T-5224

Toyama is entitled to up-front and milestone payments of up to $370M; it also would get royalties on resulting sales (6/25)

ZymoGenetics Inc. (ZGEN)

Bayer HealthCare AG

Agreement for rights outside the U.S. to recombinant human thrombin in exchange for $30M up front and another $40M upon FDA approval

ZymoGenetics also would be eligible to receive up to $128M in development and sales milestone payments, as well as royalties; Bayer will offer sales and marketing help to ZymoGenetics in the U.S. for three years following product launch; Bayer would then get a tiered commission of up to 20% of U.S. sales, as well as sales bonuses of up to $20M in total (6/19)